HK1140228A1 - Anti fgf23 antibody and pharmaceutical composition comprising the same - Google Patents

Anti fgf23 antibody and pharmaceutical composition comprising the same

Info

Publication number
HK1140228A1
HK1140228A1 HK10106310.8A HK10106310A HK1140228A1 HK 1140228 A1 HK1140228 A1 HK 1140228A1 HK 10106310 A HK10106310 A HK 10106310A HK 1140228 A1 HK1140228 A1 HK 1140228A1
Authority
HK
Hong Kong
Prior art keywords
same
pharmaceutical composition
fgf23 antibody
anti fgf23
antibody
Prior art date
Application number
HK10106310.8A
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1140228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1140228A1 publication Critical patent/HK1140228A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK10106310.8A 2007-02-14 2010-06-28 Anti fgf23 antibody and pharmaceutical composition comprising the same HK1140228A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
PCT/JP2008/052918 WO2008099969A1 (ja) 2007-02-14 2008-02-14 抗fgf23抗体及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
HK1140228A1 true HK1140228A1 (en) 2010-10-08

Family

ID=39690189

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10106310.8A HK1140228A1 (en) 2007-02-14 2010-06-28 Anti fgf23 antibody and pharmaceutical composition comprising the same
HK13100123.5A HK1172917A1 (en) 2007-02-14 2013-01-04 Anti fgf23 antibody and a pharmaceutical composition comprising the same fgf23

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13100123.5A HK1172917A1 (en) 2007-02-14 2013-01-04 Anti fgf23 antibody and a pharmaceutical composition comprising the same fgf23

Country Status (23)

Country Link
US (4) US7883705B2 (de)
EP (3) EP2502996B1 (de)
JP (1) JP4800396B2 (de)
KR (1) KR101462291B1 (de)
CN (2) CN102702355B (de)
AU (1) AU2008215346B2 (de)
CA (1) CA2677782C (de)
CY (3) CY1118835T1 (de)
DK (3) DK3181691T3 (de)
ES (3) ES2811318T3 (de)
FR (1) FR18C1032I2 (de)
HK (2) HK1140228A1 (de)
HR (2) HRP20170548T1 (de)
HU (3) HUE050517T2 (de)
LT (3) LT2502996T (de)
LU (2) LUC00082I2 (de)
NL (1) NL300945I2 (de)
NO (1) NO2018025I1 (de)
PL (3) PL2128253T3 (de)
PT (3) PT3181691T (de)
SI (2) SI2502996T1 (de)
TW (1) TWI422593B (de)
WO (1) WO2008099969A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4799801B2 (ja) * 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
EP1466925B1 (de) * 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antikörper gegen den fibroblastenwachstumsfaktor 23
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
ES2851674T3 (es) 2014-06-09 2021-09-08 Ultragenyx Pharmaceutical Inc Control efectivo y eficaz de fosfato sérico para una formación ósea óptima
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
WO2018181935A1 (ja) 2017-03-30 2018-10-04 シスメックス株式会社 抗ＡｐｏＡ１抗体
US20220185876A1 (en) * 2019-03-29 2022-06-16 Atarga, Llc Anti fgf23 antibody
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (de) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US20020102604A1 (en) 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
ES2281964T3 (es) 1998-05-18 2007-10-01 University College London Hormona polipeptidica derivada de tumor humano fosfatonina.
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
AU3924300A (en) 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666494A1 (de) 1999-12-01 2006-06-07 Genentech, Inc. Sekretierte und Transmembran-Polypeptide und für diese kodierende Nukleinsäuren
EP1246843A1 (de) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Neues fgf homolog zfgf12
AU2001239765A1 (en) 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001061007A2 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
WO2001066596A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
CN1446227B (zh) 2000-07-19 2011-10-05 先端研究与技术学院 新型成纤维细胞生长因子(fgf23)及其使用方法
JP4799801B2 (ja) 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
US20040171825A1 (en) 2001-04-26 2004-09-02 Lydie Bougueleret Human fibroblast growth factor-related compositions
EP2009027B1 (de) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Monoklonaler Antikörper gegen CD40
EP1466925B1 (de) 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antikörper gegen den fibroblastenwachstumsfaktor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
WO2004083425A1 (ja) * 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
EP1753783B1 (de) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3-antikörper und verfahren zu deren anwendung
ZA200701656B (en) * 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
CA2579391C (en) * 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
WO2006078072A1 (ja) 2005-01-21 2006-07-27 Kirin Beer Kabushiki Kaisha キメラ非ヒト動物およびその使用
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU2008215346B2 (en) 2013-01-10
LTPA2018508I1 (lt) 2018-09-10
FR18C1032I2 (fr) 2019-08-09
ES2811318T3 (es) 2021-03-11
EP2128253B1 (de) 2014-12-03
ES2530670T3 (es) 2015-03-04
DK2128253T3 (en) 2015-01-05
EP2128253A1 (de) 2009-12-02
SI2502996T1 (sl) 2017-08-31
EP3181691A1 (de) 2017-06-21
PL2502996T3 (pl) 2017-07-31
NL300945I2 (en) 2020-05-13
NO2018025I1 (no) 2018-08-09
DK3181691T3 (da) 2020-08-17
SI3181691T1 (sl) 2020-09-30
PT2502996T (pt) 2017-05-10
EP3181691B1 (de) 2020-07-15
US10202446B2 (en) 2019-02-12
HK1172917A1 (en) 2013-05-03
EP2502996B1 (de) 2017-03-29
PL3181691T3 (pl) 2020-11-02
NL300945I1 (en) 2018-08-15
JP4800396B2 (ja) 2011-10-26
TWI422593B (zh) 2014-01-11
KR20090114452A (ko) 2009-11-03
LUC00081I2 (de) 2018-10-01
US20090148461A1 (en) 2009-06-11
FR18C1032I1 (de) 2018-08-31
HRP20170548T1 (hr) 2017-08-25
PT2128253E (pt) 2015-02-04
HUE031728T2 (en) 2017-07-28
US20110182913A1 (en) 2011-07-28
CA2677782C (en) 2016-07-26
PL2128253T3 (pl) 2015-04-30
LT2502996T (lt) 2017-06-26
HUE050517T2 (hu) 2020-12-28
CY2018021I1 (el) 2019-07-10
AU2008215346A1 (en) 2008-08-21
EP2128253A4 (de) 2010-03-10
US20190106485A1 (en) 2019-04-11
HUS1800034I1 (hu) 2018-09-28
EP2502996A2 (de) 2012-09-26
CA2677782A1 (en) 2008-08-21
US7883705B2 (en) 2011-02-08
JPWO2008099969A1 (ja) 2010-05-27
KR101462291B1 (ko) 2014-11-14
DK2502996T3 (en) 2017-05-08
TW200902549A (en) 2009-01-16
US9290569B2 (en) 2016-03-22
US20160159895A1 (en) 2016-06-09
WO2008099969A1 (ja) 2008-08-21
CN101652476A (zh) 2010-02-17
CN102702355A (zh) 2012-10-03
CN102702355B (zh) 2014-09-24
LUC00082I2 (de) 2018-10-01
HRP20201266T1 (hr) 2021-02-05
EP2502996A3 (de) 2013-04-10
LTC2502996I2 (lt) 2019-05-10
LT3181691T (lt) 2020-08-25
CN101652476B (zh) 2012-07-04
CY1123240T1 (el) 2021-10-29
CY2018021I2 (el) 2019-07-10
CY1118835T1 (el) 2018-01-10
ES2625823T3 (es) 2017-07-20
PT3181691T (pt) 2020-08-26

Similar Documents

Publication Publication Date Title
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
HK1221252A1 (zh) 限制的 肽及含有其的藥物組合物
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
SI2099826T1 (sl) Anti-beta-amiloidno protitelo in njegova uporaba
EP2236604A4 (de) Anti-nr10-antikörper und verwendung davon
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
HK1203206A1 (en) Antibody and use thereof
EP2208732A4 (de) Deshydroxyvancomycin, herstellung, pharmazeutische zusammensetzung und verwendung
GB0610090D0 (en) Particulate drug compositions and their uses
EP2070919A4 (de) Spirochinonverbindung und pharmazeutische zusammensetzung
GB0614365D0 (en) Pharmaceutical compositions and their use
EP2124959A4 (de) Pharmazeutische zusammensetzung
EP2402333A4 (de) 1,4-benzothiazepin-1-oxidderivat und pharmazeutische zusammensetzung damit
EP2114404A4 (de) Pharmazeutische verbindung und zusammensetzung
AP2734A (en) Pharmaceutical carrier composition and pharmaceutical composition
EP2275437A4 (de) Polypeptid und das polypeptid enthaltende pharmazeutische zusammensetzung
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
GB0619768D0 (en) Pharmaceutical composition comprising antibodies
AP2007004032A0 (en) Pharmaceutical carrier composition and pharmaceutical composition
GB0600032D0 (en) Pharmaceutical composition
GB0612696D0 (en) Pharmaceutical composition